A Better Shot
For more than three decades, experts have understood that a gene variant called ApoE4 can greatly increase the risks of the degenerative brain condition known as Alzheimer's disease by up to 12 times. Now, a team of researchers from the Washington University School of Medicine in St. Louis have found a way to disrupt the growth of ApoE4 proteins — indicating it could one day be used to delay or prevent Alzheimer's.
ApoE4, a variant of the apolipoprotein E (ApoE) gene, is believed to promote the growth of amyloid beta proteins into plaques, known to be prominent in the brains of people suffering from Alzheimer's. The Washington University researchers found a way to disrupt ApoE4 proteins using a compound from a DNA-based molecule called antisense oligonucleotide.
"The compound blocks the production of ApoE4 by causing degradation of ApoE messenger RNA," explained David Holtzman, Department of Neurology head, in an email to Futurism. (Messenger RNA is the form of RNA that conveys what proteins should be produced, based on what they read in a DNA sequence.) "ApoE4 promotes amyloid deposition, and damage to nerve processes in the context of amyloid deposition."
Holtzman and his colleagues tested their compound by injecting it in the liquid surrounding the brains of newborn mice. A control group was given only either salt water or a placebo. Those that received the compound had their ApoE levels drop by half compared to those given only salt water or placebo.
After two months, both groups were given boosters, either of the compound or salt water.
Towards Reversing Alzheimer's
A number of studies that pursue treatments or methods to prevent Alzheimer's — a disease that affects some 44 million people worldwide, and over 5 million in the United States — focus on better understanding the mechanisms of amyloid beta plaque development or the proteins that interact with it, like ApoE.
"There is much evidence that amyloid beta is an initiating factor in a cascade of events that leads to dementia in Alzheimer’s disease," Carmela Abraham, a biochemistry professor at the Boston University School of Medicine's Pharmacology and Experimental Therapeutics unit, told Futurism. "However, there are other factors participating such as the protein tau that accumulates in neurons, and inflammation."
For their part, Holtzman expects that their compound is one that Alzheimer's patients might need to continuously take. "If taken very early on, it could potentially prevent or markedly delay [Alzheimer's]," he said. "It would probably be a compound one would need to keep taking the rest of their life once they started."
Abraham, on the other hand, suggests that a "combination of treatments that would attack amyloid, tau and inflammation has a higher chance of success." She and her colleagues at BU School of Medicine are taking a different approach: making "the neurons resilient to beta amyloid, tau and inflammation by increasing the levels of a proven neuroprotective and cognitive enhancing protein, Klotho," she explained to Futurism. Klotho is a protein that's known for its anti-aging effects.
While both Holtzman's and Abraham's teams are yet to proceed into human clinical trials, theirs aren't the only efforts that aim to defeat Alzheimer's. Others have focused on coming up with a vaccine or drug — with two already in human clinical trials — while there are those that suggest lifestyle changes. Still some are focusing on understanding the mechanisms that affect the brains of patients with Alzheimer's. With this widespread research action, it's possible that we might come up with improved treatments sooner than later.
Share This Article